JP6574848B2 - Ｃｄ１９結合ドメインを含むキメラ抗原レセプター（ｃａｒ） - Google Patents

Ｃｄ１９結合ドメインを含むキメラ抗原レセプター（ｃａｒ） Download PDF

Info

Publication number
JP6574848B2
JP6574848B2 JP2017546104A JP2017546104A JP6574848B2 JP 6574848 B2 JP6574848 B2 JP 6574848B2 JP 2017546104 A JP2017546104 A JP 2017546104A JP 2017546104 A JP2017546104 A JP 2017546104A JP 6574848 B2 JP6574848 B2 JP 6574848B2
Authority
JP
Japan
Prior art keywords
car
cell
cells
endodomain
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017546104A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018508215A5 (OSRAM
JP2018508215A (ja
Inventor
マーティン プーレ，
マーティン プーレ，
レイラ メッカオウイ，
レイラ メッカオウイ，
パーシス アムロリア，
パーシス アムロリア，
サラ ゴラシアン，
サラ ゴラシアン，
アン クレイマー，
アン クレイマー，
ゴードン チェン，
ゴードン チェン，
Original Assignee
ユーシーエル ビジネス ピーエルシー
ユーシーエル ビジネス ピーエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユーシーエル ビジネス ピーエルシー, ユーシーエル ビジネス ピーエルシー filed Critical ユーシーエル ビジネス ピーエルシー
Publication of JP2018508215A publication Critical patent/JP2018508215A/ja
Publication of JP2018508215A5 publication Critical patent/JP2018508215A5/ja
Application granted granted Critical
Publication of JP6574848B2 publication Critical patent/JP6574848B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
JP2017546104A 2015-03-05 2016-03-04 Ｃｄ１９結合ドメインを含むキメラ抗原レセプター（ｃａｒ） Active JP6574848B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1503742.7 2015-03-05
GB201503742A GB201503742D0 (en) 2015-03-05 2015-03-05 Chimeric antigen receptor
PCT/GB2016/050574 WO2016139487A1 (en) 2015-03-05 2016-03-04 Chimeric antigen receptor (car) comprising a cd19-binding domain

Publications (3)

Publication Number Publication Date
JP2018508215A JP2018508215A (ja) 2018-03-29
JP2018508215A5 JP2018508215A5 (OSRAM) 2019-03-07
JP6574848B2 true JP6574848B2 (ja) 2019-09-11

Family

ID=52998440

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017546104A Active JP6574848B2 (ja) 2015-03-05 2016-03-04 Ｃｄ１９結合ドメインを含むキメラ抗原レセプター（ｃａｒ）

Country Status (15)

Country Link
US (3) US10457730B2 (OSRAM)
EP (1) EP3265490B1 (OSRAM)
JP (1) JP6574848B2 (OSRAM)
CN (1) CN107406517B (OSRAM)
AU (1) AU2016227498B2 (OSRAM)
CA (1) CA2978381C (OSRAM)
DK (1) DK3265490T3 (OSRAM)
ES (1) ES2732067T3 (OSRAM)
FR (1) FR25C1040I1 (OSRAM)
GB (1) GB201503742D0 (OSRAM)
HU (2) HUE044298T2 (OSRAM)
PL (1) PL3265490T3 (OSRAM)
PT (1) PT3265490T (OSRAM)
TR (1) TR201909647T4 (OSRAM)
WO (1) WO2016139487A1 (OSRAM)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6788573B6 (ja) 2014-04-10 2020-12-16 シアトル チルドレンズ ホスピタル， ディービーエー シアトル チルドレンズ リサーチ インスティテュート メトトレキサートによる選択と組み合わせたＳｌｅｅｐｉｎｇ Ｂｅａｕｔｙトランスポゾンによる遺伝子改変Ｔ細胞の製造
EP3805371A1 (en) 2014-05-15 2021-04-14 National University of Singapore Modified natural killer cells and uses thereof
PT3560953T (pt) 2014-12-24 2024-03-26 Autolus Ltd Célula
GB201503742D0 (en) * 2015-03-05 2015-04-22 Ucl Business Plc Chimeric antigen receptor
CA2994829A1 (en) 2015-08-07 2017-02-16 Seattle Children's Hospital (dba Seattle Children's Research Institute) Bispecific car t-cells for solid tumor targeting
US9681109B2 (en) * 2015-08-20 2017-06-13 Qualcomm Incorporated Systems and methods for configurable demodulation
WO2017180587A2 (en) 2016-04-11 2017-10-19 Obsidian Therapeutics, Inc. Regulated biocircuit systems
IL269553B2 (en) * 2017-03-27 2025-10-01 Nat Univ Singapore Truncated NKG2D chimeric receptors and their uses in immunotherapy with natural killer cells
MX2019011570A (es) 2017-03-27 2019-11-18 Nat Univ Singapore Lineas celulares estimuladoras para expansion y activacion ex vivo de celulas asesinas naturales.
CN107098981B (zh) * 2017-06-29 2020-05-01 青岛麦迪赛斯医疗技术有限公司 一种靶向cd19的嵌合抗原受体修饰的t淋巴细胞
JP2020530993A (ja) * 2017-08-02 2020-11-05 オートラス リミテッド キメラ抗原受容体または改変ｔｃｒを発現し、選択的に発現されるヌクレオチド配列を含む細胞
CN111465616B (zh) 2017-12-06 2023-08-01 艾克隆株式会社 特异性识别恶性b细胞的抗体或其抗原结合片段、包含其的嵌合抗原受体及其用途
CN107903326B (zh) * 2018-01-02 2020-06-30 广东省人民医院(广东省医学科学院) 包含C3aR胞内结构域的嵌合抗原受体、慢病毒载体、表达细胞及药物
CN108047332B (zh) * 2018-01-15 2021-08-24 阿思科力(苏州)生物科技有限公司 以cd19为靶点的特异性抗体、car-nk细胞及其制备和应用
US12258381B2 (en) 2018-02-09 2025-03-25 National University Of Singapore Activating chimeric receptors and uses thereof in natural killer cell immunotherapy
EP3757133A4 (en) * 2018-02-11 2021-12-01 Jiangsu Hengrui Medicine Co., Ltd. ISOLATED ANTIGENIC CHEMICAL RECEPTOR, MODIFIED T LYMPHOCYTE INCLUDING IT AND ASSOCIATED USE
CN112055717B (zh) 2018-04-02 2024-04-26 新加坡国立大学 用在免疫细胞中表达的膜结合抗细胞因子非信号传导粘合剂中和人细胞因子
CN110372796B (zh) * 2018-04-12 2023-05-02 上海赛比曼生物科技有限公司 靶向bcma的嵌合抗原受体及其制法和应用
CN112119096B (zh) 2018-05-15 2024-04-30 奥托路斯有限公司 嵌合抗原受体
GB201807870D0 (en) 2018-05-15 2018-06-27 Autolus Ltd A CD79-specific chimeric antigen receptor
CN108794642A (zh) * 2018-07-05 2018-11-13 宁波安诺柏德生物医药科技有限公司 一种嵌合抗原细胞受体及其应用
CN110819678A (zh) * 2018-08-07 2020-02-21 上海恒润达生生物科技有限公司 一种评估cart细胞有效性的方法
CN110850068B (zh) * 2018-08-21 2023-08-15 上海恒润达生生物科技股份有限公司 一种嵌合抗原受体亲和力检测方法
EP3844186A4 (en) 2018-08-29 2022-08-17 National University of Singapore METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS
MX2021003636A (es) * 2018-09-27 2021-07-21 Autolus Ltd Receptor antigenico quimerico.
GB201816522D0 (en) 2018-10-10 2018-11-28 Autolus Ltd Methods and reagents for analysing nucleic acids from single cells
WO2020092839A1 (en) 2018-10-31 2020-05-07 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
WO2020092736A1 (en) 2018-10-31 2020-05-07 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
AU2019372673A1 (en) 2018-11-01 2021-05-27 Gracell Biotechnologies (Shanghai) Co., Ltd. Compositions and methods for T cell engineering
CN109468282B (zh) * 2018-11-22 2019-06-18 青岛协和华美医学诊断技术有限公司 一种靶向cd19的嵌合抗原受体t细胞的制备方法及应用
CN109734813B (zh) * 2019-01-28 2022-06-17 广东昭泰体内生物医药科技有限公司 一种嵌合抗原受体及其应用
EP3912992A4 (en) * 2019-02-04 2022-11-23 National University Corporation Ehime University Car library and production method for scfv
US12419913B2 (en) 2019-02-08 2025-09-23 Dna Twopointo, Inc. Modification of CAR-T cells
WO2020167912A1 (en) 2019-02-13 2020-08-20 The Brigham And Women's Hospital, Inc. Anti-peripheral lymph node addressin antibodies and uses thereof
KR20210137085A (ko) 2019-03-05 2021-11-17 엔카르타, 인크. Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도
GB201903237D0 (en) 2019-03-08 2019-04-24 Autolus Ltd Method
CN113543792A (zh) * 2019-03-08 2021-10-22 奥托路斯有限公司 包含工程化嵌合抗原受体和car调节剂的组合物和方法
WO2020247392A1 (en) * 2019-06-04 2020-12-10 Nkarta, Inc. Combinations of engineered natural killer cells and engineered t cells for immunotherapy
CN114729383A (zh) 2019-07-02 2022-07-08 弗莱德哈钦森癌症研究中心 重组ad35载体及相关基因疗法改进
CN114286683B (zh) * 2019-07-17 2024-10-01 新加坡国立大学 由免疫细胞合成和分泌的功能性结合物
EP4021485A1 (en) * 2019-08-28 2022-07-06 King's College London B cell targeted parallel car (pcar) therapeutic agents
JP2023512452A (ja) * 2020-01-13 2023-03-27 ンカルタ・インコーポレイテッド Ｂｃｍａ指向性細胞免疫療法組成物および方法
EP4114449A2 (en) 2020-03-05 2023-01-11 Neotx Therapeutics Ltd. Methods and compositions for treating cancer with immune cells
CN113402612A (zh) 2020-03-17 2021-09-17 西比曼生物科技（香港）有限公司 靶向cd19和cd20的联合嵌合抗原受体及其应用
GB202005216D0 (en) 2020-04-08 2020-05-20 Autolus Ltd Cell
KR20230010228A (ko) * 2020-05-08 2023-01-18 시애틀 칠드런즈 호스피탈 디/비/에이 시애틀 칠드런즈 리서치 인스티튜트 자연 살해 세포를 표적으로 하는 키메라 항원 수용체 (cars)
WO2022031597A1 (en) 2020-08-03 2022-02-10 Kyverna Therapeutics, Inc. Methods of producing t regulatory cells, methods of transducing t cells, and uses of the same
WO2022072515A1 (en) * 2020-09-29 2022-04-07 Washington University Methods to determine risk of neurotoxicity
CN116635064A (zh) 2020-12-18 2023-08-22 世纪治疗股份有限公司 具有适应性受体特异性的嵌合抗原受体系统
EP4271817A2 (en) 2020-12-30 2023-11-08 Alaunos Therapeutics, Inc. Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof
WO2022165419A1 (en) 2021-02-01 2022-08-04 Kyverna Therapeutics, Inc. Methods for increasing t-cell function
US20240181055A1 (en) * 2021-04-08 2024-06-06 Crage Medical Co., Limited Cellular immunotherapy use
CN117088975B (zh) * 2022-05-11 2024-06-25 东莞市朋志生物科技有限公司 抗白蛋白抗体、检测白蛋白的试剂和试剂盒
EP4522204A1 (en) 2022-05-11 2025-03-19 Autolus Limited Cd19/22 car t-cell treatment of high risk or relapsed pediatric acute lymphoblastic leukemia
CN116253794B (zh) * 2022-08-19 2025-04-04 首都医科大学宣武医院 一种用于car-t细胞调控的抗体及其应用
AU2024244733B2 (en) 2023-03-31 2025-12-11 AbelZeta Inc. Bispecific chimeric antigen receptors targeting cd20 and bcma
CN121219004A (zh) 2023-05-30 2025-12-26 奥托路斯有限公司 复发性/难治性b细胞急性成淋巴细胞性白血病的cd19car t细胞治疗
WO2025008642A1 (en) 2023-07-05 2025-01-09 Autolus Limited Method
CN119350497A (zh) * 2023-07-24 2025-01-24 星尘生物科技(上海)有限公司 人源化抗cd19单链可变区片段及其用途
GB202316184D0 (en) 2023-10-23 2023-12-06 Autolus Ltd Method
WO2025088308A1 (en) 2023-10-23 2025-05-01 Autolus Limited Products and methods for treating autoimmune diseases
EP4574838A1 (en) 2023-12-21 2025-06-25 Vilnius University Chimeric antigen receptor (car) with enhanced recruitment of signaling partners
GB202403564D0 (en) 2024-03-12 2024-04-24 Autolus Ltd Method
WO2025215360A1 (en) 2024-04-09 2025-10-16 Autolus Limited Method

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102421800A (zh) 2009-02-23 2012-04-18 格兰马克药品股份有限公司 结合cd19的人源化抗体及其用途
CN104159909A (zh) 2012-02-22 2014-11-19 宾夕法尼亚大学董事会 产生用于癌症治疗的t细胞持续性群体的组合物和方法
RU2727447C2 (ru) * 2013-05-13 2020-07-21 Селлектис Cd19-специфический химерный антигенный рецептор и его применения
PT3560953T (pt) 2014-12-24 2024-03-26 Autolus Ltd Célula
GB201503742D0 (en) * 2015-03-05 2015-04-22 Ucl Business Plc Chimeric antigen receptor

Also Published As

Publication number Publication date
AU2016227498B2 (en) 2019-05-02
CA2978381C (en) 2019-11-05
US20230220077A1 (en) 2023-07-13
PT3265490T (pt) 2019-07-16
US20200140544A1 (en) 2020-05-07
EP3265490A1 (en) 2018-01-10
AU2016227498A1 (en) 2017-08-31
JP2018508215A (ja) 2018-03-29
US20180044417A1 (en) 2018-02-15
CA2978381A1 (en) 2016-09-09
US10457730B2 (en) 2019-10-29
EP3265490B1 (en) 2019-05-08
HUE044298T2 (hu) 2019-10-28
WO2016139487A1 (en) 2016-09-09
ES2732067T3 (es) 2019-11-20
GB201503742D0 (en) 2015-04-22
CN107406517A (zh) 2017-11-28
PL3265490T3 (pl) 2019-10-31
CN107406517B (zh) 2020-05-12
TR201909647T4 (tr) 2019-07-22
HUS2500036I1 (hu) 2025-09-28
DK3265490T3 (en) 2020-05-11
US11578126B2 (en) 2023-02-14
FR25C1040I1 (fr) 2025-11-21

Similar Documents

Publication Publication Date Title
JP6574848B2 (ja) Ｃｄ１９結合ドメインを含むキメラ抗原レセプター（ｃａｒ）
JP7379561B2 (ja) キメラ抗原及びｔ細胞受容体、並びに使用方法
JP7514746B2 (ja) 細胞
KR102618231B1 (ko) 변형된 만능성 줄기 세포, 및 제조 및 사용 방법
Gill et al. Going viral: chimeric antigen receptor T‐cell therapy for hematological malignancies
US9446105B2 (en) Chimeric antigen receptor specific for folate receptor β
US20210324087A1 (en) Cll1-targeting antibody and application thereof
CN111247242A (zh) 嵌合抗原受体(CARs)、组合物及其使用方法
WO2020063787A1 (zh) 抗b7-h3的单克隆抗体及其在细胞治疗中的应用
US20240368282A1 (en) Methods and compositions for stimulating immune activity
CA3103337A1 (en) Nef-containing t cells and methods of producing thereof
CN111848809A (zh) 靶向Claudin18.2的CAR分子、其修饰的免疫细胞及用途
US20230226181A1 (en) GENETIC ENGINEERING OF gamma delta T CELLS FOR IMMUNOTHERAPY
WO2022116952A1 (zh) 靶向cd70的抗原结合蛋白及其应用
CN112041432A (zh) Foxp3靶向剂组合物以及用于过继细胞疗法的使用方法
JP2025516531A (ja) 高リスクまたは再発性小児急性リンパ芽球性白血病のｃｄ１９／２２ ｃａｒ ｔ細胞処置
HK1242341B (en) Chimeric antigen receptor (car) comprising a cd19-binding domain
HK1242341A1 (en) Chimeric antigen receptor (car) comprising a cd19-binding domain
WO2025191260A1 (en) Treatment of autoimmune disease by co-expression of cd19-car and bcma-car
CN118742319A (zh) 具有抗cd19/抗cd22嵌合抗原受体的基因工程化细胞及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181220

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190124

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20190124

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20190207

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190301

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190521

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190703

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190725

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190808

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190819

R150 Certificate of patent or registration of utility model

Ref document number: 6574848

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250